Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 19/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4352915 | 1.00 | HSD11B1 (0.77) | HSD11B1CYP3A4CYP2D6CYP2C9HSD11B2 | |
| SCHEMBL4534774 | 0.89 | HSD11B1 (0.92) | HSD11B1HSD11B2NR1I2 | |
| SCHEMBL4532443 | 0.87 | HSD11B1 (1.00) | HSD11B1HSD11B2NR1I2 | |
| SCHEMBL12020550 | 0.82 | HSD11B1 (0.78) | HSD11B1CYP3A4CYP2D6CYP2C9NR1I2 | |
| SCHEMBL827055 | 0.82 | HSD11B1 (0.78) | HSD11B1CYP3A4CYP2D6CYP2C9NR1I2 | |
| SCHEMBL827054 | 0.82 | HSD11B1 (0.78) | HSD11B1CYP3A4CYP2D6CYP2C9NR1I2 | |
| SCHEMBL4524293 | 0.79 | HSD11B1 (0.74) | HSD11B1HSD11B2NR1I2 | |
| SCHEMBL4535544 | 0.78 | HSD11B1 (0.82) | HSD11B1HSD11B2NR1I2 | |
| SCHEMBL4531723 | 0.75 | HSD11B1 (0.73) | HSD11B1CYP3A4CYP2D6CYP2C9HSD11B2 | |
| SCHEMBL12020514 | 0.75 | HSD11B1 (0.73) | HSD11B1CYP3A4CYP2D6CYP2C9HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532122-B1 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2009073460-A2 | INHIBITION OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 FOR OCULAR NEUROPROTECTION | BAUSCH & LOMB INCORPORATED (US) | 2009-06-11 | — | — | WO | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-6730690-B2 | DELAYING THE ONSET OR REDUCING THE RISK OF DEVELOPING ATHEROSCLEROSIS IN A HUMAN PATIENT COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A COMPOUND OF INVENTION AND AN HMG-COA REDUCTASE INHIBITOR | MERCK & CO., INC. | 2004-05-04 | — | — | US | disclosed |